^
Association details:
| Biomarker: | STEAP1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | vandortuzumab vedotin (RG7450) (Microtubule inhibitor, STEAP1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Excerpt:
DSTP3086S has acceptable safety at the recommended phase II dose level of 2.4 mg/kg once every 3 weeks. Antitumor activity at doses between 2.25 and 2.8 mg/kg once every 3 weeks supports the potential benefit of treating STEAP1-expressing metastatic castration-resistant prostate cancer with an STEAP1-targeting antibody-drug conjugate.
DOI:
https://doi.org/10.1200/JCO.19.00646
Trial ID:
